Submission guidelines

Material offered for publication must be original, unpublished and not under simultaneous consideration by another journal. Any previous publication of the material (including abstracts in conference proceedings or posters, or in a clinical trials results database) must be declared in the covering letter, as well as in the Acknowledgements section of the paper.

Submission of a manuscript to a Revista Española de Quimioterapia (REQ) implies that all authors have read and agreed to its content and that the manuscript conforms to the journal’s policies.

Aims and scope

REQ publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents primarily in human medicine. The Journal particularly welcomes manuscripts on: the practice of evidence-based medicine relating to antimicrobials (clinical trials, systematic reviews and meta-analyses); antimicrobial treatment (pharmacokinetics, pharmacodynamics and prescribing practices); the action of antimicrobial agents and the mechanisms, genetics and epidemiology of antimicrobial resistance; antimicrobial stewardship, and the genetic basis of antimicrobial resistance. Case reports related to infectious diseases current research related to the laboratory diagnosis of human and the role of the laboratory in both the management of infectious diseases and the elucidation of the epidemiology of infections also are welcome

Top

Editorial office contact information

The contact details for the REQ Editorial Office are as follows:

Sociedad Española de Quimioterapia

Área de Microbiología, Departamento de Medicina, Universidad Complutense de Madrid

Avda  Complutense s/n

28040 Madrid (Spain)

Phone: +34913941512

E-mail: info@seq.es

Processing of papers

All material (manuscript with/without figures ) to be considered for publication should be submitted by e-mail: revista@seq.es

License agreement will be submitted to revista@seq.es once a manuscript number was assigned.

 Article types and format

All documents should be double spaced, legible single font, and point size should be employed throughout. All submitted articles should be line numbered (using continuous line numbers). All articles should include a title page comprising: article title; author names and their affiliations (each affiliation address must be given separately and in full); telephone, fax and e-mail contact details for the corresponding author; and a short running title. In addition, all articles must include a Funding section (if reporting original research) and a Conflicts of interest section.

    – Abstract

Original articles and Brief reports must have a structured synopsis (Abstract in English/ Resumen en Español). Both must have a 250 words maximum. The headings for the structured synopsis are as follows: Objectives, Patients and methods (or Material and methods), Results, and Conclusions. Review articles must have a synopsis (250 words maximum). Five keywords must be included immediately after the abstract.

    – Original articles

There is a limit of 4000 words in the main text of the article (everything from the Introduction to the end of the Discussion). Papers must be written as concisely as possible. Original articles are divided into the following sections: Abstract (250 words maximum), Introduction, Patients and methods (or Material and methods), Results, Discussion, Acknowledgements, Funding, Conflicts of interest, and References. Repetition of content between sections must be avoided. A combined Results and Discussion section is acceptable.

    – Brief reports

These should have the same format as Original articles, but should have no more than three figures/tables, should have a maximum of 20 references and should not exceed 1500 words of main text.

    – Letters (case reports)

Letters on topics of concern or interest in the field of antimicrobial chemotherapy, particularly arising from papers or letters already published in the Journal. These should be addressed to the Editor-in-Chief and must not exceed 800 words, no more than two figures/tables and 10 references. REQ will publish Case reports that are of sufficient calibre and potential importance, and they should be submitted in the form of Correspondence Please note that patient anonymity must be preserved in Case reports (see Ethics and patient consent/privacy).

    – Systematic review articles

There is no length limit for this format. They should include a structured synopsis (with appropriate headings; these may differ from the headings used for Original articles).

    – Review articles

There is no length limit for this format. These generally aim to give an overview of a field suitable for a wide audience, and they should include a synopsis (250 words maximum). Most reviews are invited. We are pleased to consider unsolicited reviews, but authors are encouraged to consult the Editor-in-Chief in advance of writing to avoid duplicating commissioned material.

   Journal style

Manuscripts in English and Spanish are welcome.

The past tense should be used throughout for description of the results of the paper, the present tense should be used when referring to previously established and generally accepted results.

Non-standard abbreviations should be defined at the first occurrence and introduced only where multiple use is made.

Please note that all MIC data in REQ must be expressed in terms of mg/L (not μg/mL).

   Tables

Please submit tables as editable text and not as images. Tables should be included as part of the manuscript text after the References section. Number tables consecutively in accordance with their appearance in the text and place any table notes above the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article.

   Figures

Figures should be sent separately and not be included as part of the manuscript text. Choose ppt. files from Power Point, TIFF or JPEG. Color or grayscale photographs, keep to a minimum of 300 dpi.

   References

All references, including URLs, must be numbered consecutively, in square brackets, in the order in which they are cited in the text, followed by any in tables or legends. Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either ‘Unpublished results’ or ‘Personal communication’. Citation of a reference as ‘in press’ implies that the item has been accepted for publication. A PMID number from PUBMED or DOI must be included at the end of the reference.

Examples:

Reference to a journal publication: García-Agudo L, Rodríguez-Iglesias M, Carranza-González R, Galán F, Asencio MA, Huertas Vaquero M et al. Urinary tract infection in the oldest old: a work overload for the microbiology laboratory. Rev Esp Quimioter. 2017;30(5):379-81. https://www.ncbi.nlm.nih.gov/pubmed/28749124

Reference to a book:  Weiner WJ, Lang AE. Movement disorders. A comprehensive survey. Nueva York: Futura Publishing Company, 1989.

Reference to a chapter in an edited book: Wiestler OD, Radner H. Pathology of neurofibromatosis 1 and 2. In: Huson SM, Hughes RAC, editores. Theneurofibromatoses. A pathogenetic and clinical overview. Londres: Chapman Hall Medical, 1994;p 135-59.

Reference to a website: Cancer Research UK. Cancer statistics reports for the UK, http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/; 2017 [accessed 15 March 2017].

Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of one independent expert reviewer to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor’s decision is final.

Proofs, Late corrections, Advance Access and Errata

Corresponding authors will receive an e-mail with a PDF to our Editorial Office, allowing annotation and record your edits on the PDF version. Extensive changes at the proof stage are not permitted.  Authors must treat the proof as the last chance they will have to make corrections to their article. Once all the corrections have been made, the article is then posted on REQ Advance Access. REQ Advance Access is the Journal’s system for the early online publication of articles ahead of the bimonthly  journal issue. Corrections that are requested once an article has appeared in Advance Access will entail a higher level of scrutiny. The Journal takes a very dim view of corrections requested at this stage that should have been dealt with earlier, and reserves the right to refuse to make further changes. After publication in print, the only avenue available to correct an article is the publication of a linked Erratum. The purpose of an Erratum is to correct items that affect the scientific validity of a piece of research.

Offprints

Orders must be sent to the Publisher (Sociedad Española de Quimioterapia):  info@seq.es

Editorial policies

Open Access

REQ is free of charge journal. Authors sign a license agreement, where authors have copyright but license exclusive rights in their article to the publisher (this includes the right for the publisher to authorize commercial use). In this case authors have the right to:

  • Share their article in the same ways permitted to third parties under the relevant user license (together with Personal Use rights) and a link to the version of record.
  • Retain patent, trademark and other intellectual property rights (including research data).
  • Proper attribution and credit for the published work.

The article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Authors may not use the material for commercial purposes.

Ethics

All articles in REQ describing research in humans or animals must include an ‘Ethics’ heading as the first section in the Patients and methods or Methods section. Authors must include in this section all relevant statements regarding approvals, licences, informed consent and so on, as applicable.

   Research involving humans

Authors must indicate in the Ethics section whether the research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. If approval was obtained from an Ethics Committee the authors must clearly name the ethics committee responsible if more than one institution is involved. The approval/reference number must be listed in the Ethics section of the article.

       Consent to participate

Written informed consent must be obtained from study participants and the existence of this consent must be stated in the article. Authors must supply the relevant approval numbers from Ethics committees or other bodies.

       Patient privacy

Patients have a right to privacy. Any information that might result in identification of individuals must be omitted, especially if it is not directly clinically relevant.

   Research involving animals

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments,  and the authors should clearly indicate in the manuscript that such guidelines have been followed.

Funding

All papers submitted to REQ reporting original research must include a “Funding” section. This section should appear after the “Acknowledgements” section. Details of all funding sources for the work in question must be given. The sentence should begin: “This work was supported by …” or state if there are none “None to declare”.

Conflicts of interest

REQ requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a “Conflicts of interest” section before the Reference section the listing all competing interests (financial and non-financial). Where authors have no Conflicts of interest, the statement should read “The author(s) declare(s) that they have no conflicts of interest”. The Editor may ask for further information relating to competing interests. Editors and reviewers are also required to declare any competing interests and may be excluded from the peer review process if a competing interest exists.

Authorship

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted. All contributors who do not meet the criteria for authorship should be listed in an ‘Acknowledgements’ section. Examples of those who might be acknowledged include a person who provided purely technical help or writing assistance, or a department chair who provided only general support.

REQ  recommends that authors review the ICMJE criteria for authorship before submission (  http://www.icmje.org/#author).

Changes to authorship

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor.

Clinical trials

Authors must register their trials in one of the databases dedicated to registration of trials. In addition, authors must state the database and provide the unique registration number, both in the abstract and in the main body of the paper.

Misconduct

We will energetically pursue accusations of misconduct directed at authors, Editors or referees. Accusations should not be made lightly or in the absence of the likelihood of supporting evidence being obtainable. The Journal may take the view that accusations are malicious if supporting evidence cannot be found and may direct sanctions against accusers in such cases. Any accusation of misconduct should be addressed to the Editor-in-Chief.